Bonjour

Connexion
Rejoindre

2023-02-06

Respiratory Syncytial Virus or Flu? Know RSV Symptoms and Treatment

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. This blog post describes the causes, prevalence, and preventive measures of RSV. 

What Is RSV? 

RSV is also called respiratory syncytial virus. The virus causes respiratory infections, which can range from mild to life-threatening. It is spread through respiratory droplets and is highly contagious. The virus doesn’t produce long-lasting immunity, so reinfection is possible. 

RSV is considered a seasonal virus. In North America, it is most prevalent from late fall until early spring. 

Symptoms of RSV

Symptoms of RSV usually appear within 2 to 8 days of exposure. In toddlers, children, and adults, the most common symptoms include the following:

  • Congestion
  • Cough
  • Headache
  • Fatigue
  • Fever
  • Sore throat
  • Runny nose

In babies, RSV may cause fussiness, decreased appetite, and changes to breathing patterns. 

In most cases, RSV remains mild, and symptoms resolve within 7 to 14 days. RSV can progress to bronchiolitis, which is a lower respiratory tract infection with small airway obstruction. In rare cases, it can develop into pneumonia. Severe cases of RSV can result in respiratory failure, apnea, or death. 

Signs of severe illness include:

  • Noisy breathing
  • Flaring of nostrils with every breath
  • Blue or gray tinge around lips, mouth, and fingernails
  • Laboured breathing or belly breathing
  • Short, shallow, slow, or rapid breathing
  • Pauses while breathing

What Population Is at Risk for RSV? 

Everyone is susceptible to RSV. Experts estimate that 90 percent of children experience RSV before they are two years old. Older children and adults can have multiple infections due to a lack of long-term immunity to the virus. The virus is mild or asymptomatic in the vast majority of cases among adults and children 12 months and older.

People with certain risk factors are at greater risk of RSV progressing to a more serious lower respiratory infection. Babies younger than six months are the most likely to develop severe infection. Other high-risk groups include:

  • Infants with heart or lung conditions
  • Premature infants
  • Children who have difficulty swallowing or clearing mucus
  • Immunocompromised children and adults
  • Adults over age 65
  • Adults with congestive heart failure, chronic obstructive pulmonary disease, or asthma

How Prevalent Is RSV?

RSV is extremely common. There are an estimated 64 million worldwide infections annually. RSV results in 3.4 million hospitalizations and an estimated 10,000 deaths worldwide per year. 

What Is the Difference Between Flu and RSV? 

Influenza, or flu, is also a viral illness that causes respiratory infection. It has many of the same symptoms as RSV, including coughing, runny nose, fever, and headaches. Flu is more likely to have a sudden onset of symptoms. Flu is also more likely to cause significant fatigue and body aches than RSV.

Testing is available for both flu and RSV. Providers can administer rapid antigen tests or PCR tests in-office. There are combination tests that detect RSV, influenza, and COVID-19. In some locations, at-home tests are available over the counter. 

How To Treat RSV

Mild RSV symptoms can be treated with home care. Children and adults may benefit from over-the-counter medication such as acetaminophen or ibuprofen to control fever. Rest, fluids, adequate nutrition, and a cool mist humidifier can ease symptoms and encourage recovery. 

If RSV progresses to a more serious condition, medical attention is required. Patients may need hospitalization, IV fluids, and oxygen support. 

There is one anti-viral medication – ribavirin – approved for the treatment of RSV infection in infants and, in combination with interferon α2b, hepatitis C. It is typically only recommended for patients with underlying conditions that compromise immune function. It is not indicated for patients receiving ventilation. 

How To Prevent RSV

Standard hygiene and infection control practices can reduce the risk of contracting RSV. Providers can advise patients to protect themselves through:

  • Frequent hand washing using soap and water
  • Cleaning and sanitizing frequently touched surfaces, objects, and toys
  • Keeping children home from school or daycare when they are ill
  • Avoiding contact with people who are ill
  • Limiting time in large group settings

People at high risk of complications due to RSV may be candidates for the prophylactic drug Palivizumab. This medication can reduce the risk of severe illness from RSV. Paliviumad is administered as a monthly injection during the RSV season.

To learn more about RSV and how to manage the care of patients during the peak season, explore our courses on RSV:

Join the MDBriefCase community for free to stay current on clinical guidelines. 

Recent Blogs

199 Bay Street #4000, Toronto,
ON M5L 1A9

Compagnie
Aider
Juridique
think-research-logo-green
© 2024. Tous droits réservés. Think Research Corporation.
Get Briefed

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.

Audience and Appropriate Topics

The  Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.

Parameters

Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words. 

Review

MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.